Compare Gilead Sciences, Inc. (GILD) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs InMode Ltd — how do they compare? Gilead Sciences, Inc. trades at $132.94 (market cap $163.51B), while InMode Ltd trades at $15.46 (market cap $878.31M). The key difference: Gilead Sciences, Inc. is far larger — about 186.2× InMode Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| GILD | INMD | |
|---|---|---|
Market Cap | $163.51B | $878.31M |
Sector | Health | Technology |
52-Week High | $155.80 | $16.62 |
52-Week Low | $108.22 | $12.76 |
Enterprise Value | $178.05B | $345.98M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
INMD trades at $15.36, up 2.92% today, with a bullish technical signal from moving averages. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, while valuation ratios appear attractive with a P/E of 11.32. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and Q2 2026 revenue guidance of $95.2M-$95.4M.
The stock presents a mixed outlook: upside exists from potential acquisition interest and solid fundamentals, but risks include a recent earnings miss, ongoing securities fraud investigations, and overbought technical indicators. Analyst consensus is divided with a $16.50 price target suggesting moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
